Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2019
Pharmacy Choice - Pharmaceutical News - Findings on Laryngeal Cancer Reported by Researchers at University of Helsinki and Helsinki University Hospital (Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of ...) - January 20, 2019

Pharmacy News Article

 12/28/18 - Findings on Laryngeal Cancer Reported by Researchers at University of Helsinki and Helsinki University Hospital (Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of ...)

By a News Reporter-Staff News Editor at Cancer Weekly Fresh data on Oncology - Laryngeal Cancer are presented in a new report. According to news reporting originating from Helsinki, Finland, by NewsRx correspondents, research stated, "Biomarkers that could predict malignant transformation of recurrent respiratory papillomatosis (RRP) would be useful in patient follow-up. We investigated whether serum matrix metalloproteinase 8 (MMP-8) and tissue inhibitor of metalloproteinase 1 (TIMP-1) could predict malignant transformation of RRP and whether they associate with survival in laryngeal squamous cell carcinoma (LSCC) without preexisting RRP."

Our news editors obtained a quote from the research from the University of Helsinki and Helsinki University Hospital, "We analyzed serum MMP-8 (S-MMP-8) and serum TIMP-1 (s-TIMP-1) in 114 patients: 55 were treated for RRP and 59 for LSCC without preexisting RRP. Five patients with RRP developed LSCC during follow-up. Elevated S-MMP-8 level in RRP was associated with malignant transformation (p=.01). Compared to patients with RRP, S-MMP-8 in patients with LSCC was significantly higher (p <.001). Increased S-TIMP-1 level in LSCC was associated with poor overall survival (p=.02) and recurrence-free survival (p=.05). In RRP, high S-MMP-8 may predict malignant transformation."

According to the news editors, the research concluded: "In LSCC, elevated S-TIMP-1 is connected to poor survival."

For more information on this research see: Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer. Head & Neck, 2018;():. (Wiley-Blackwell - www.wiley.com/; Head & Neck - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0347)

The news editors report that additional information may be obtained by contacting P.P. Pakkanen, Dept. of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Additional authors for this research include L.M. Aaltonen, T.A. Sorsa, T.I. Tervahartiala, J.K. Hagstrom and T.T Ilmarinen (see also Oncology - Laryngeal Cancer).

(Our reports deliver fact-based news of research and discoveries from around the world.)



Copyright 2019, NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jan 20: An Integrative Approach to Managing Arthritis
Last Chance
Jan 21: Identifying, Targeting and Managing Chronic Renal Failure
Jan 22: Medication Use During Pregnancy & Lactation
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415